Can specialized HIV community pharmacies improve treatment?

August 14, 2012
©2012 Mary Ann Liebert Inc., publishers

Community pharmacies with specially trained staff to provide HIV services can help HIV-infected individuals be more compliant with their essential antiviral drug regimens and hence improve patient outcomes. Users of HIV-specialized Walgreen pharmacies across the U.S. had significantly greater adherence to and persistence with their therapeutic drug regimens according to a study published in AIDS Patient Care and STDs.

Patricia Murphy, MPH and coauthors from Walgreen Co. and University of California San Francisco School of Pharmacy compared therapeutic anti- adherence (the degree to which patients follow their prescribed drug regimen) and persistence (the time to treatment discontinuation) for HIV/AIDS patients who used HIV-specialized pharmacies or traditional community pharmacies during the time span of a year. The study, "Impact of HIV Specialized Pharmacies on Adherence and Persistence with Antiretroviral Therapy," followed patients in nine cities across seven states. The researchers propose that their results should demonstrate the value of implementing policies to encourage the use of specialized HIV pharmacies for filling antiviral prescriptions.

"While antiretroviral treatments have dramatically increased the health and life expectancy of people infected with HIV, and helped to slow HIV transmission, these medications only work if taken on a regular basis," says Editor-in-Chief Jeffrey Laurence, MD, Director of the Laboratory for Research at Weill Medical College of Cornell University, New York, NY. "Enlisting pharmacies in a multi-pronged approach to maintaining is critical. This study demonstrates the role of the pharmacist in this important endeavor."

Explore further: African-Americans face roadblocks to HIV therapy, untreated depression makes it worse

More information: The article is available free on the AIDS Patient Care and STDs website at http://www.liebertpub.com/apc.

Related Stories

Are there gender differences in anti-HIV drug efficacy?

August 9, 2012

Women comprise nearly half of the HIV-infected population worldwide, but these 15.5 million women tend to be under-represented in clinical trials of anti-HIV drug therapies. The U.S. Food and Drug Administration (FDA) has ...

Recommended for you

Targeting HIV in semen to shut down AIDS

August 18, 2015

There may be two new ways to fight AIDS—using a heat shock protein or a small molecule - to attack fibrils in semen associated with the human immunodeficiency virus (HIV) during the initial phases of infection, according ...

HVTN 505 vaccine induced antibodies nonspecific for HIV

July 30, 2015

A study by researchers at the National Institute of Allergy and Infectious Diseases and Duke University helps explain why the candidate vaccine used in the HVTN 505 clinical trial was not protective against HIV infection ...

Vitamin D status related to immune response to HIV-1

June 15, 2015

Vitamin D plays an important part in the human immune response and deficiency can leave individuals less able to fight infections like HIV-1. Now an international team of researchers has found that high-dose vitamin D supplementation ...

Why HIV's cloak has a long tail

June 2, 2015

Virologists at Emory University School of Medicine, Yerkes National Primate Research Center, and Children's Healthcare of Atlanta have uncovered a critical detail explaining how HIV assembles its infectious yet stealthy clothing.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.